MX2017007978A - 3-(piperidin-4-il)-isoxazol-3(2h)-onas para tratamiento de trastornos dermatologicos. - Google Patents

3-(piperidin-4-il)-isoxazol-3(2h)-onas para tratamiento de trastornos dermatologicos.

Info

Publication number
MX2017007978A
MX2017007978A MX2017007978A MX2017007978A MX2017007978A MX 2017007978 A MX2017007978 A MX 2017007978A MX 2017007978 A MX2017007978 A MX 2017007978A MX 2017007978 A MX2017007978 A MX 2017007978A MX 2017007978 A MX2017007978 A MX 2017007978A
Authority
MX
Mexico
Prior art keywords
isoxazol
treatment
piperidin
ones
dermatologic disorders
Prior art date
Application number
MX2017007978A
Other languages
English (en)
Inventor
Fex Tomas
David Gustafsson Nils
Original Assignee
Emeriti Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emeriti Pharma Ab filed Critical Emeriti Pharma Ab
Publication of MX2017007978A publication Critical patent/MX2017007978A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Descritos son un grupo de análogos de isoxazol-3(2H)-ona y su uso en formulaciones tópicas para el tratamiento y profilaxis de trastornos dermatológicos.
MX2017007978A 2014-12-19 2015-12-18 3-(piperidin-4-il)-isoxazol-3(2h)-onas para tratamiento de trastornos dermatologicos. MX2017007978A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462094278P 2014-12-19 2014-12-19
PCT/SE2015/051369 WO2016099397A1 (en) 2014-12-19 2015-12-18 3-(piperidin-4-yl)-isoxazol-3(2h)-ones for treatment of dermatologic disorders

Publications (1)

Publication Number Publication Date
MX2017007978A true MX2017007978A (es) 2017-09-29

Family

ID=55310879

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007978A MX2017007978A (es) 2014-12-19 2015-12-18 3-(piperidin-4-il)-isoxazol-3(2h)-onas para tratamiento de trastornos dermatologicos.

Country Status (10)

Country Link
US (2) US20170360766A1 (es)
EP (1) EP3233189A1 (es)
JP (1) JP2017537935A (es)
KR (1) KR20170095839A (es)
CN (1) CN107207484A (es)
AU (1) AU2015363700A1 (es)
BR (1) BR112017008835A2 (es)
CA (1) CA2967268A1 (es)
MX (1) MX2017007978A (es)
WO (1) WO2016099397A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018619A2 (en) * 2001-08-24 2003-03-06 Micrologix Biotech Inc. Antimicrobial and anti-inflammatory peptides
CN109942687B (zh) * 2018-10-16 2020-07-03 哈尔滨医科大学 68Ga标记EACA修饰c-Met分子成像探针及制备与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5711723B2 (ja) 2009-04-07 2015-05-07 エメリティ・ファーマ・アクチボラグ 治療剤としてのイソオキサゾール−３（２ｈ）−オン類似体
WO2012047156A1 (en) * 2010-10-04 2012-04-12 Astrazeneca Ab Isoxazol-3(2h)-one analogs as plasminogen inhibitors and their use in the treatment of fibrinolysis related diseases

Also Published As

Publication number Publication date
JP2017537935A (ja) 2017-12-21
KR20170095839A (ko) 2017-08-23
CN107207484A (zh) 2017-09-26
CA2967268A1 (en) 2016-06-23
WO2016099397A1 (en) 2016-06-23
US20180338964A1 (en) 2018-11-29
BR112017008835A2 (pt) 2018-03-27
EP3233189A1 (en) 2017-10-25
AU2015363700A1 (en) 2017-04-27
US20170360766A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
EP3328492B8 (en) Phototherapy devices for treatment of dermatological disorders of the scalp
HK1252821A1 (zh) 用於治療具有rtk突變細胞的患者的組合物和方法
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
HK1247843A1 (zh) 具有受控吸收曲線的用於口服給藥活性劑的製劑
PT3377637T (pt) Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele
IL252943A0 (en) Sunitinib formulations and methods of using them for the treatment of eye diseases
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
IL246855A0 (en) Materials for use in the treatment of retinitis
MX2017007978A (es) 3-(piperidin-4-il)-isoxazol-3(2h)-onas para tratamiento de trastornos dermatologicos.
EP3148556A4 (en) Skin treatment formulations
EP3119387A4 (en) Compositions for the treatment of dermatological diseases and disorders
MX2016011706A (es) Formulaciones de progesterona.
PL3515409T3 (pl) Kompleks i kompozycje do leczenia chorób okulistycznych i dermatologicznych
IL248428B (en) 3,1-propanedisulfonic acid or its pharmaceutically acceptable salt for use in the treatment of sarcoidosis
ZA201806894B (en) (+)-azasetron for use in the treatment of ear disorders
EP3386516A4 (en) PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF SKIN DISORDERS AND METHODS OF MAKING AND USING THE SAME
EP3226865A4 (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
PT3442537T (pt) (+)-azasetrom para utilização no tratamento de doenças do ouvido
AU2015904022A0 (en) Implants for the Treatment of Diseases and Disorders
EP3261630A4 (en) Compositions and combinations for the treatment of angiogenesis diseases and disorders
EP3247396A4 (en) Methods and compositions for the treatment of diseases and disorders